4.8 Article

DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability

期刊

ONCOGENE
卷 41, 期 33, 页码 3991-4002

出版社

SPRINGERNATURE
DOI: 10.1038/s41388-022-02404-9

关键词

-

资金

  1. National Natural Science Foundation of China [82173060, 82072649]
  2. Outstanding Youth Foundation of Jiangsu Province [BK20200046]
  3. National Postdoctoral Research Funds of China [2019M651971, 2021T140577]
  4. Postgraduate Research & Practice Innovation Program of Jiangsu [KYCX21_2689]
  5. Jiangsu Provincial Key Medical Discipline
  6. Project of Invigorating Health Care through Science, Technology and Education [ZDXKA2016014]
  7. Qinglan Project of Jiangsu

向作者/读者索取更多资源

This study reveals the molecular interplay between DNA methyltransferase DNMT1 and histone methyltransferase EZH2 in the development and metastasis of prostate cancer. We found that high expression of DNMT1 promotes PC cell proliferation and migration by inhibiting TRAF6 transcriptional expression and TRAF6-mediated EZH2 ubiquitination. Our results also show that targeting DNMT1 with its inhibitor Decitabine can suppress tumor growth and metastasis through epigenetic regulation of DNMT1-mediated DNA methylation and EZH2-mediated histone methylation.
A plethora of studies have shown that both DNMT1 and EZH2 have great effects on the progression of a variety of cancers. However, it remains unclear whether the expression profiles of these two epigenetic enzymes are molecularly intertwined in prostate cancer (PC), especially in castration-resistant prostate cancer (CRPC). Here, we found that DNMT1 is highly expressed and facilitates PC cell proliferation and migration. Importantly, we demonstrate that the abrogation of DNMT1 expression can induce the decreased expression of EZH2, resulting in the less aggressive capacity of PC cells. Mechanistically, we discovered that DNMT1 promotes PC tumorigenesis and metastasis by inhibiting TRAF6 transcriptional expression and subsequent TRAF6-mediated EZH2 ubiquitination. Finally, we confirmed that there is a negative correlation between DNMT1 and TRAF6 expression and a positive correlation between DNMT1 and EZH2 expression in PC patients. In this study, we first disclose that there is a direct crosstalk between DNA methyltransferase DNMT1 expression and histone methyltransferase EZH2 expression in tumorigenesis and cancer metastasis in vitro and in vivo. Our results also show that targeting DNMT1 with its inhibitor decitabine (an FDA-approved drug) is an appealing treatment strategy for CRPC patients through epigenetic suppression of both DNMT1-mediated DNA methylation and EZH2-modulated histone methylation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据